Alzamend Competitors

Stocks . USA . 
Stock . Alzamend Neuro
ALZN Stock  USD 2.01  0.07  3.37%   
Alzamend Neuro competes with Biocardia, Creative Medical, HCW Biologics, Acurx Pharmaceuticals, and Aprea Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Alzamend Neuro competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Alzamend Neuro to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Alzamend Neuro Correlation with its peers.
To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.

Alzamend Neuro vs Phio Pharmaceuticals Correlation

Good diversification

The correlation between Alzamend Neuro and PHIO is -0.1 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Alzamend Neuro and PHIO in the same portfolio, assuming nothing else is changed.

Moving against Alzamend Stock

  0.47EQ EquilliumPairCorr
  0.4ALSEN Sensorion SAPairCorr
  0.33CMB Cambium BioPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.102.016.17
Details
Intrinsic
Valuation
LowRealHigh
1.818.4312.59
Details
Naive
Forecast
LowNextHigh
0.052.446.60
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
2.012.012.01
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Alzamend Neuro. Your research has to be compared to or analyzed against Alzamend Neuro's peers to derive any actionable benefits. When done correctly, Alzamend Neuro's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Alzamend Neuro.

Alzamend Neuro Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Alzamend Neuro and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Alzamend and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Alzamend Neuro does not affect the price movement of the other competitor.

High positive correlations

ACXP
+ 0.94
HCWB
ADIL
+ 0.93
HCWB
ADIL
+ 0.92
ACXP
ADIL
+ 0.78
BCDA
HCWB
+ 0.77
CELZ
APRE
+ 0.77
CELZ
  

High negative correlations

KPRX
- 0.54
APRE
CDIO
- 0.4
KPRX
KPRX
- 0.38
CELZ
KPRX
- 0.3
ACXP
KPRX
- 0.27
HCWB
PHIO
- 0.24
KPRX

Risk-Adjusted Indicators

There is a big difference between Alzamend Stock performing well and Alzamend Neuro Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Alzamend Neuro's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
BCDA  2.47 (0.07) 0.00 (0.12) 0.00 
 0.00 
 5.93 
(6.03)
 19.36 
CELZ  3.58 (0.70) 0.00 (0.22) 0.00 
 0.00 
 7.17 
(9.64)
 25.03 
HCWB  4.41 (2.04) 0.00 (0.98) 0.00 
 0.00 
 8.11 
(11.97)
 42.74 
ACXP  3.95 (1.50) 0.00 (1.30) 0.00 
 0.00 
 6.31 
(8.54)
 49.19 
APRE  4.50 (0.21) 0.00 (0.09) 0.00 
 0.00 
 11.29 
(10.58)
 46.26 
ADIL  3.16 (1.58) 0.00 (2.33) 0.00 
 0.00 
 5.70 
(8.24)
 34.48 
KPRX  2.42  0.14  0.05  0.27  2.52 
(2.79)
 4.44 
(3.90)
 16.69 
NRSN  4.22 (0.22) 0.00 (0.13) 0.00 
 0.00 
 12.50 
(7.37)
 28.83 
CDIO  9.04  2.02  0.31  0.65  6.07 
(12.61)
 25.48 
(13.93)
 80.69 
PHIO  4.55  0.17  0.03  0.21  5.60 
(5.65)
 7.34 
(9.65)
 56.33 

Alzamend Neuro Competitive Analysis

The better you understand Alzamend Neuro competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Alzamend Neuro's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Alzamend Neuro's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ALZN BCDA CELZ HCWB ACXP APRE ADIL KPRX NRSN CDIO
 3.37 
 2.01 
Alzamend
 4.03 
 1.29 
Biocardia
 1.63 
 1.81 
Creative
 1.82 
 0.54 
HCW
 8.54 
 1.50 
Acurx
 4.55 
 0.92 
Aprea
 3.69 
 2.53 
Adial
 0.48 
 2.09 
Kiora
 1.11 
 0.91 
Neurosense
 25.48 
 6.55 
Cardio
Market Volatility
(90 Days Market Risk)
Slightly risky
Moderately volatile
Moderately volatile
Moderately volatile
Somewhat reliable
Dangerous
Slightly risky
Very risky
Very risky
Moderately volatile
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Soft
Weakest
Good
Odds of Financial Distress
(Probability Of Bankruptcy)
Risky
Risky
Strong
Risky
Risky
Risky
Risky
Low
High
Small
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Buy
Buy
Strong Buy
Strong Buy
Strong Buy
Buy
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Hold
Strong Sell
Cautious Hold
Current Ratio
11.78
3.0
58.88
30.25
19.43
7.45
5.32
1.53
15.09
18.42
Net Asset
4.6 M
3.72 M
6.67 M
30.24 M
3.86 M
23.98 M
5.04 M
36.48 M
4.58 M
10.62 M
EBITDA
(4.45 M)
(7.93 M)
(5.63 M)
(27.68 M)
(14.1 M)
(14.3 M)
(8.28 M)
5.7 M
(9.88 M)
(8.09 M)
Current Valuation
7.45 M
9.04 M
949.84 K
7.48 M
(2.09 M)
(7.31 M)
(1.8 M)
(11.28 M)
26.42 M
6.09 M
Price To Book
1.72
5.21
1.13
2.8
1.05
0.59
0.62
0.34
12.82
1.47
Operating Margin
N/A
N/A
N/A
-528.87
N/A
N/A
N/A
N/A
N/A
-599.51
Retained Earnings
(58.54 M)
(160.12 M)
(64.59 M)
(100.56 M)
(67.32 M)
(321.04 M)
(82 M)
(143.38 M)
(36.66 M)
(22.75 M)
Current Asset
N/A
19.48 M
N/A
N/A
N/A
39.28 M
1.02 M
N/A
N/A
N/A
Beta
-0.24
0.61
2.07
0.64
-1.22
1.61
1.24
-0.81
1.57
2.87
Number Of Employees
4
17
4
36
4
8
5
12
17
13
Shares Outstanding
3.8 M
10.61 M
3.49 M
2.15 M
2.55 M
6.99 M
1.11 M
3.68 M
29.55 M
1.83 M
Cash Flow From Operations
(6.57 M)
(8.03 M)
(5.3 M)
(14.23 M)
(10.38 M)
(13.56 M)
(6.92 M)
8.56 M
(10.13 M)
(4.99 M)
Total Debt
634.76 K
951 K
14.19 K
13.69 M
3.24 M
4.67 M
975.86 K
57.17 K
73 K
969.86 K
Return On Equity
-1.45
-3.17
-0.98
-277.26
-2.91
-0.75
-1.55
-0.33
-24.78
-1.11
Return On Asset
-0.73
-0.86
-0.6
-0.3
-0.96
-0.42
-0.79
-0.17
-3.04
-0.62
Number Of Shares Shorted
263.39 K
236.14 K
343.46 K
23.76 K
73.79 K
255.05 K
33.64 K
8.67 K
392.04 K
122.52 K
Book Value Per Share
1.15
0.25
2.17
-0.024
2.02
1.83
4.72
6.53
-0.021
4.61
Current Liabilities
N/A
330 K
N/A
N/A
N/A
5.96 M
452.53 K
N/A
N/A
N/A
Total Asset
4.6 M
3.72 M
6.67 M
30.24 M
3.86 M
23.98 M
5.04 M
36.48 M
4.58 M
10.62 M
Short Ratio
2.91
3.3
3.77
0.54
1.82
0.05
0.82
0.11
1.15
0.88
Target Price
28.0
15.5
20.0
35.0
61.7
5.33
26.0
12.0
11.5
60.0
Debt To Equity
N/A
0.26
N/A
0.005
0.026
0.005
0.029
0.018
0.019
N/A
Shares Owned By Institutions
6.46
6.12
7.57
2.24
8.76
24.26
12.7
22.05
1.71
7.09
Market Capitalization
7.64 M
13.69 M
6.33 M
5.36 M
3.82 M
6.41 M
2.81 M
7.69 M
27.11 M
11.96 M
Price To Earning
N/A
-11.0
-54.81
N/A
N/A
-9.54
-1.88
N/A
N/A
N/A
Price To Sales
N/A
3089.53
1054.22
4.2
N/A
13.13
N/A
363.74
N/A
757.87
Net Income
(4.51 M)
(7.95 M)
(5.49 M)
(30.02 M)
(14.1 M)
(12.96 M)
(13.2 M)
3.59 M
(10.21 M)
(8.38 M)
Earnings Per Share
-2.67
-1.42
-2.84
-16.41
-8.18
-2.12
-15.0
-2.19
-0.36
-11.91
Shares Owned By Insiders
2.17
26.66
1.0
27.3
5.05
19.62
2.08
2.98
25.55
6.79
Revenue
N/A
58 K
11 K
2.57 M
N/A
1.5 M
N/A
16 M
N/A
34.89 K
Working Capital
3.54 M
301 K
5.81 M
(23.93 M)
615.12 K
20.22 M
3.08 M
23.7 M
2.41 M
8.16 M
Cash And Equivalents
11.53 M
8.61 M
22.86 M
32.41 M
9.09 M
39.06 M
9.16 M
2.43 M
10.37 M
9.66 M
Cash Per Share
0.12
0.49
1.62
0.9
0.8
1.67
0.35
2.64
0.89
5.08
Gross Profit
N/A
(5.25 M)
3.6 K
166.57 K
N/A
(7.91 M)
N/A
(3.72 M)
N/A
15.78 K
Day Typical Price
2.02
1.28
1.81
0.55
1.54
0.89
2.54
2.12
0.9
6.74
Accumulation Distribution
0.0529
0.0534
0.0378
0.1
0.0976
0.11
0.0608
0.0548
0.0435
0.27
Market Facilitation Index
0.11
0.07
0.07
0.06
0.16
0.1
0.16
0.12
0.04
2.16
Daily Balance Of Power
(0.64)
0.7143
(0.43)
(0.17)
(0.88)
0.4
0.5625
(0.08)
0.25
0.6157
Period Momentum Indicator
(0.07)
0.05
(0.03)
(0.01)
(0.14)
0.04
0.09
(0.01)
0.01
1.33
Rate Of Daily Change
0.97
1.04
0.98
0.98
0.91
1.05
1.04
1.0
1.01
1.25
Day Median Price
2.03
1.27
1.82
0.55
1.56
0.87
2.55
2.13
0.9
6.83
Price Action Indicator
(0.05)
0.04
(0.02)
(0.01)
(0.13)
0.07
0.025
(0.04)
0.015
0.38
Relative Strength Index
24.85
18.05
38.54
19.76
10.45
0.57
9.72
70.05
55.34
21.4
Coefficient Of Variation
19404.27
(12,566)
(977.94)
(344.53)
(469.01)
(7,622)
(317.83)
1423.23
(4,514)
655.77
Mean Deviation
3.07
2.47
3.58
4.41
3.95
4.5
3.16
2.42
4.22
9.04
Jensen Alpha
0.0066
(0.07)
(0.70)
(2.04)
(1.50)
(0.21)
(1.58)
0.1437
(0.22)
2.02
Total Risk Alpha
(0.42)
(0.41)
(1.02)
(2.56)
(2.11)
(0.90)
(2.03)
(0.11)
(0.73)
0.7184
Sortino Ratio
(0.02)
N/A
N/A
N/A
N/A
N/A
N/A
0.0452
N/A
0.3139
Downside Variance
14.11
N/A
N/A
N/A
N/A
N/A
N/A
7.47
N/A
49.98
Standard Deviation
4.16
3.58
4.91
6.46
6.6
7.53
4.81
3.04
5.72
15.14
Kurtosis
0.7871
3.23
1.22
3.13
19.04
8.45
9.34
1.42
1.09
12.18
Potential Upside
7.89
5.93
7.17
8.11
6.31
11.29
5.7
4.44
12.5
25.48
Treynor Ratio
0.1886
(0.12)
(0.22)
(0.98)
(1.30)
(0.09)
(2.33)
0.2723
(0.13)
0.6487
Maximum Drawdown
19.96
19.36
25.03
42.74
49.19
46.26
34.48
16.69
28.83
80.69
Variance
17.32
12.81
24.08
41.78
43.57
56.78
23.17
9.23
32.7
229.28
Market Risk Adjusted Performance
0.1986
(0.11)
(0.21)
(0.97)
(1.29)
(0.08)
(2.32)
0.2823
(0.12)
0.6587
Risk Adjusted Performance
0.0121
0.0018
(0.07)
(0.21)
(0.15)
(0)
(0.23)
0.0613
(0.01)
0.1262
Skewness
0.4546
0.452
0.1703
0.3063
3.4
1.61
(1.89)
0.7251
0.3173
3.06
Semi Deviation
3.54
N/A
N/A
N/A
N/A
N/A
N/A
2.52
N/A
6.07
Information Ratio
(0.02)
(0.03)
(0.12)
(0.30)
(0.23)
(0.03)
(0.33)
0.0407
(0.04)
0.1466
Value At Risk
(6.48)
(6.03)
(9.64)
(11.97)
(8.54)
(10.58)
(8.24)
(3.90)
(7.37)
(13.93)
Expected Short fall
(3.82)
N/A
N/A
N/A
N/A
N/A
N/A
(2.79)
N/A
(12.61)
Downside Deviation
3.76
N/A
N/A
N/A
N/A
N/A
N/A
2.73
N/A
7.07
Semi Variance
12.52
N/A
N/A
N/A
N/A
N/A
N/A
6.37
N/A
36.81

Alzamend Neuro Competition Performance Charts

Five steps to successful analysis of Alzamend Neuro Competition

Alzamend Neuro's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Alzamend Neuro in relation to its competition. Alzamend Neuro's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Alzamend Neuro in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Alzamend Neuro's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Alzamend Neuro, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Alzamend Neuro position

In addition to having Alzamend Neuro in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Hybrid Mix Funds Thematic Idea Now

Hybrid Mix Funds
Hybrid Mix Funds Theme
Funds or Etfs that are made of portfolios of stocks, bonds, or cash instruments with different maturity horizons and characteristics. The Hybrid Mix Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hybrid Mix Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Alzamend Neuro offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alzamend Neuro's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alzamend Neuro Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alzamend Neuro Stock:
How To Invest In Alzamend
Details
Is Alzamend Stock a good investment?
Details
What is Alzamend Neuro's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Alzamend Neuro Correlation with its peers.
To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Biotechnology sector continue expanding? Could Alzamend diversify its offerings? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Alzamend Neuro data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Understanding that Alzamend Neuro's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Alzamend Neuro represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Alzamend Neuro's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY